About CLINUVEL

Dr Philippe Wolgen

MBA, MD

Chief Executive Officer, Managing Director

Having been recognised for his strategic mindset and meticulous business execution, Dr Wolgen has brought to the Company his international finance experience and professional contacts to European capital markets. As a former equity analyst, his in-depth analysis and expertise of the life science sector has been an asset to CLINUVEL. He held positions in private pharmaceutical companies in Europe, as MD of two medical centres in the UK and Israel, and consulted medical device companies. He has been instrumental in raising $86 million since 2006 for the funding of the current development program of SCENESSE® (afamelanotide 16mg).

Dr Wolgen holds an MBA from Columbia University NY and the London Business School. Trained as a craniofacial surgeon, Dr Wolgen holds an MD from the University of Utrecht, the Netherlands.

 

Latest Company Announcements

09 August 2017

Form 604, 09 August 2017

Notice of change of interests of substantial holder

Read More
31 July 2017

Appendix 4C - Quarterly report

Appendix 4C

Read More
25 July 2017

CLINUVEL Newsletter - July 2017

For those who have followed the Company over the years, the journey of our teams has most often been counter-current to arrive at the present point.

Read More
10 May 2017

Appendix 3B

Appendix 3B

Read More
10 May 2017

CLINUVEL Newsletter - May 2017

I look back at a turbulent period, as CLINUVEL has brought the ‘negotiations’ with GKV-Spitzenverband (National Association of Statutory Health Insurance Funds in Germany) to a successful end.

Read More
02 May 2017

NICE ENGLAND UPDATE ON SCENESSE®

CLINUVEL announce that the Department of Health has designated SCENESSE® to be evaluated as a Highly Specialised Technology (HST)

Read More

Quick Links